Risks associated with mass-produced compounded GLP-1s Although the FDA has declared that the supply shortage is resolved, some companies continue to mass produce compounded versions of GLP-1s, claiming that the drugs are personalized for patient needs by altering the method of delivery (e.g., gummy, injection, spray) or adding unnecessary and unproven ingredients like B12 and glycine
These findings underscore the need to monitor who is accessing these medications and to ensure their safe, appropriate, and equitable provision
Results Timelines Individual responses to BPC-157 vary considerably based on injury severity, administration method, dosage, and individual physiology
[12] Conteduca V, Di Tullio P, Allamprese R, et al